Stock listing
NASDAQ:CMND Clearmind Medicine Inc. Stock
Home listing (NASDAQ) of Clearmind Medicine Inc.
Follow Clearmind Medicine Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CMND
$2.63 USD -0.43 (-14.2%)
Close on Nov 20, 2026
- Day range
- $2.63 – $3.28 USDNov 20, 2026
- Volume
- 9,837 sharesNov 20, 2026
- Market cap
- $1.33M USDAt the close on Nov 20, 2026 · price × 507,404 shares outstanding
- 52-week range
- $2.63 – $694.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $102,341 USDMedian day 4,993 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CMND · Home | $2.63 USD | -0.435 (-14.2%) | 9,837 | $3.09 | $3.28 | $2.63 | $3.065 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CMND · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.63 | -0.435 | -14.2% | $3.09 | $3.28 | $2.63 | 9,837 | |
| $3.065 | -0.385 | -11.2% | $3.45 | $3.45 | $3.03 | 4,993 | |
| $3.45 | -0.733 | -17.5% | $4.00 | $4.00 | $3.24 | 12,554 | |
| $4.183 | -0.347 | -7.7% | $4.24 | $4.25 | $4.00 | 5,173 | |
| $4.53 | -0.09 | -1.9% | $4.52 | $4.785 | $4.35 | 3,426 | |
| $4.62 | -0.33 | -6.7% | $4.775 | $4.811 | $4.62 | 10,502 | |
| $4.95 | -0.14 | -2.8% | $5.415 | $5.579 | $4.93 | 5,603 | |
| $5.09 | -0.41 | -7.5% | $5.76 | $5.76 | $5.09 | 6,941 | |
| $5.50 | -0.084 | -1.5% | $5.70 | $5.77 | $5.40 | 5,070 | |
| $5.584 | -0.266 | -4.6% | $5.71 | $5.71 | $5.40 | 13,405 | |
| $5.85 | -0.07 | -1.2% | $5.925 | $5.99 | $5.60 | 3,512 | |
| $5.92 | 0.00 | 0.0% | $5.992 | $6.107 | $5.81 | 3,492 | |
| $5.92 | -0.22 | -3.6% | $5.81 | $6.10 | $5.43 | 4,681 | |
| $6.14 | -0.079 | -1.3% | $6.02 | $6.14 | $6.02 | 1,827 | |
| $6.219 | +0.369 | +6.3% | $5.83 | $6.499 | $5.83 | 9,470 | |
| $5.85 | -0.21 | -3.5% | $6.15 | $6.15 | $5.85 | 4,301 | |
| $6.06 | +0.093 | +1.6% | $6.00 | $6.10 | $5.98 | 5,022 | |
| $5.967 | -0.154 | -2.5% | $6.095 | $6.095 | $5.948 | 5,341 | |
| $6.121 | +0.251 | +4.3% | $5.92 | $6.20 | $5.86 | 16,232 | |
| $5.87 | -0.13 | -2.2% | $6.255 | $6.255 | $5.87 | 8,342 | |
| $6.00 | +0.06 | +1.0% | $6.01 | $6.04 | $6.00 | 5,297 | |
| $5.94 | -0.18 | -2.9% | $6.253 | $6.253 | $5.94 | 5,216 | |
| $6.12 | +0.12 | +2.0% | $5.971 | $6.14 | $5.91 | 6,974 | |
| $6.00 | -0.26 | -4.2% | $6.164 | $6.362 | $5.91 | 8,271 | |
| $6.26 | -0.16 | -2.5% | $6.33 | $6.47 | $6.26 | 4,137 | |
| $6.42 | +0.131 | +2.1% | $6.24 | $6.79 | $6.24 | 5,684 | |
| $6.289 | +0.059 | +0.9% | $6.36 | $6.47 | $6.20 | 10,814 | |
| $6.23 | -0.31 | -4.7% | $6.50 | $6.73 | $6.23 | 11,000 | |
| $6.54 | -0.04 | -0.6% | $6.52 | $6.80 | $6.481 | 16,100 | |
| $6.58 | -0.02 | -0.3% | $6.77 | $6.94 | $6.35 | 9,100 | |
| $6.60 | 0.00 | 0.0% | $6.64 | $7.16 | $6.40 | 41,100 | |
| $6.60 | +0.76 | +13.0% | $5.75 | $6.70 | $5.54 | 146,400 | |
| $5.84 | -0.16 | -2.7% | $5.89 | $6.175 | $5.701 | 35,400 | |
| $6.00 | +0.28 | +4.9% | $5.93 | $6.54 | $5.25 | 89,200 | |
| $5.72 | -0.008 | -0.1% | $5.92 | $5.92 | $5.648 | 1,522 | |
| $5.728 | -0.712 | -11.1% | $6.00 | $6.096 | $5.672 | 3,428 | |
| $6.44 | -0.048 | -0.7% | $6.52 | $6.72 | $6.40 | 1,559 | |
| $6.488 | +0.184 | +2.9% | $6.256 | $6.576 | $6.256 | 538 | |
| $6.304 | -0.12 | -1.9% | $6.40 | $6.544 | $6.264 | 1,422 | |
| $6.424 | -0.056 | -0.9% | $6.72 | $6.72 | $6.416 | 886 | |
| $6.48 | -0.32 | -4.7% | $6.808 | $6.808 | $6.40 | 978 | |
| $6.80 | +0.552 | +8.8% | $6.432 | $6.80 | $6.24 | 5,839 | |
| $6.248 | -0.08 | -1.3% | $6.24 | $6.32 | $6.176 | 1,169 | |
| $6.328 | -0.064 | -1.0% | $6.32 | $6.40 | $6.20 | 1,883 | |
| $6.392 | -0.472 | -6.9% | $6.80 | $6.864 | $6.16 | 2,991 | |
| $6.864 | +0.416 | +6.5% | $6.592 | $8.48 | $6.504 | 24,967 | |
| $6.448 | -0.464 | -6.7% | $6.728 | $6.776 | $6.32 | 2,399 | |
| $6.912 | -0.64 | -8.5% | $7.344 | $7.464 | $6.664 | 2,613 | |
| $7.552 | -0.184 | -2.4% | $7.52 | $7.76 | $7.336 | 2,561 | |
| $7.736 | -0.12 | -1.5% | $8.00 | $8.48 | $7.60 | 4,433 | |
| $7.856 | -0.624 | -7.4% | $8.00 | $8.36 | $7.84 | 1,581 | |
| $8.48 | +0.24 | +2.9% | $8.56 | $8.88 | $8.00 | 5,134 | |
| $8.24 | -1.04 | -11.2% | $9.20 | $9.20 | $7.36 | 48,711 | |
| $9.28 | -4.32 | -31.8% | $11.96 | $12.44 | $9.28 | 242,381 | |
| $13.60 | -1.20 | -8.1% | $14.48 | $14.72 | $13.60 | 922 | |
| $14.80 | +0.16 | +1.1% | $14.80 | $14.96 | $14.32 | 694 | |
| $14.64 | -0.88 | -5.7% | $15.44 | $15.44 | $14.08 | 3,378 | |
| $15.52 | +1.44 | +10.2% | $14.56 | $16.80 | $14.48 | 11,170 | |
| $14.08 | -0.40 | -2.8% | $14.56 | $14.72 | $13.84 | 384 | |
| $14.48 | +0.72 | +5.2% | $14.80 | $14.80 | $14.00 | 1,019 | |
| $13.76 | +0.08 | +0.6% | $13.44 | $13.92 | $13.28 | 567 | |
| $13.68 | +0.24 | +1.8% | $13.52 | $14.00 | $13.20 | 664 | |
| $13.44 | -0.48 | -3.4% | $14.00 | $14.00 | $12.88 | 1,516 | |
| $13.92 | +0.08 | +0.6% | $13.92 | $14.68 | $13.92 | 717 | |
| $13.84 | -1.44 | -9.4% | $15.44 | $15.44 | $13.60 | 1,709 |
Splits
4 splits since 2023 · NASDAQ:CMND · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-8 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-40 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- NASDAQ:CMND
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
Latest news
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
Nov 19, 2026
Closed $2.63 (-14.2%) on Nov 20, 2026
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
Nov 16, 2026
Closed $4.18 (-7.7%) on Nov 16, 2026
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
Nov 10, 2026
Closed $5.09 (-7.5%) on Nov 10, 2026
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Oct 27, 2026
Closed $5.97 (-2.5%) on Oct 27, 2026
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Oct 8, 2026
Closed $6.60 (0.0%) on Oct 8, 2026
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Oct 7, 2026
Closed $6.60 (+13.0%) on Oct 7, 2026
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Sep 23, 2026
Closed $6.80 (+8.8%) on Sep 23, 2026
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Sep 17, 2026
Closed $6.86 (+6.5%) on Sep 17, 2026
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Sep 11, 2026
Closed $7.74 (-1.5%) on Sep 11, 2026
Clearmind Medicine Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 68 in the last 12 months · 167 in all · newest Nov 19, 2026 · oldest 2022
- Decks
- 4 decks · latest November 2025
Where Clearmind Medicine Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CMND · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CMND | BOATS | United States | USD |
| gettex:CWY | gettex | Germany | EUR |
| Lang & Schwarz:A41YK5 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41YK5 | LS Exchange | Germany | EUR |
| Frankfurt:CWY0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A427B1 | Lang & Schwarz | Germany | EUR |
| Munich:CWY | Munich | Germany | USD |
| Munich:CWY0 | Munich | Germany | EUR |
Valuation
Price/book 0.2× against a median of 0.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: Year to Oct 31, 2025 · balance Jan 31, 2026 · price Nov 20, 2026
- Enterprise value
- −$9.01M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.29
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Clearmind Medicine Inc. · NASDAQ:CMND | US$1.33M | −US$9.01M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.29 |
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Kairos Pharma, Ltd. · AMEX:KAPA | US$1.48M | −US$1.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.36 |
| BioRestorative Therapies, Inc. · NASDAQ:BRTX | US$1.45M | −US$2.11M | n/a | −5.9× | n/a | 0.5× | n/a | 0.0× | 1.81 |
| Nutra Pharma Corp. · OTC:NPHC | US$1.43M | US$13.99M | n/a | 87.0× | n/a | n/a | n/a | n/a | n/a |
| Aptevo Therapeutics Inc. · NASDAQ:APVO | US$1.40M | −US$2.88M | n/a | n/a | n/a | 0.4× | n/a | 1.0× | 0.93 |
| Agentix Corp. · OTC:AGTX | US$1.35M | US$1.34M | n/a | n/a | n/a | n/a | n/a | n/a | -0.73 |
| Artelo Biosciences, Inc. · NASDAQ:ARTL | US$1.30M | US$1.34M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.36 |
| International Stem Cell Corporation · OTC:ISCO | US$1.28M | −US$18.76M | 0.1× | −2.0× | n/a | 0.1× | 222.6% | 0.0× | -0.52 |
| SureNano Science Ltd · CSE:SURE | US$1.17M | US$672,367 | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.25 |
| Median of the others | US$1.42M | −US$488,473 | 0.1× | −2.0× | 0.3× | 222.6% | 0.0× | 1.36 |
Team and board
Officers
| Officer | Role |
|---|---|
| Adi Zuloff-Shani | CEO |
| Alan Rootenberg | Chief Financial Officer |
| Gadi Levin | VP Finance |
| Mark Haden | VP Business Development |
| Adi Varon | Controller |
| Mary-Elizabeth Gifford | Chief of Global Impact |
| Mylene Touboul | Accounting Manager |
Board
| Director | Role |
|---|---|
| Amitay Weiss | Chairman of the Board |
| Asaf Itzhaik | Director |
| Hila Kiron-Revach | Director |
| Oz Adler | Director |
| Yehonatan Shachar | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Jul 31, 2026 | Sep 10, 2026 | −8.8% |
| Quarter to Apr 30, 2026 | Jun 15, 2026 | −6.0% |
| Q4 2025 | Jan 20, 2026 | +2.4% |
| Q3 2025 | Sep 11, 2025 | −0.4% |
| Q2 2025 | Jun 12, 2025 | −3.5% |
| Q1 2025 | Mar 13, 2025 | +0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2025) | Investor deck | 24 slides | November 2025 |
| Investor Presentation (July 2025) | Investor deck | 24 slides | Jul 29, 2025 |
| Investor Presentation (October 2024) | Investor deck | 19 slides | October 2024 |
| Investor Presentation (August 2024) | Investor deck | 13 slides | Aug 20, 2024 |
Financings
| Raise | Date |
|---|---|
| Convertible promissory notes Tranche closed: US$500,000 raised · Aegis Capital Corp. Dealers: Aegis Capital Corp. Use of proceeds: Working capital, general corporate purposes and potential acquisitions to support exploration of strategic opportunities | Sep 19, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.50 a share on Nov 14, 2022.
- Price
- US$6.50 a share
- Shares offered
- 1,153,847 common shares
- Offering size
- US$7.5 million
- Underwriters' option
- Up to 173,077 more shares
- Listing
- CMND on the Nasdaq Capital Market
- Underwriter
- Aegis Capital Corp.
- Shares delivered
- On or about Nov 17, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 27, 2021 |
| Filed publicly | Jun 29, 2022 |
| Amended 9 times | Newest Nov 14, 2022 |
| Shares registered with an exchange | Nov 9, 2022 |
| Declared effective by the SEC | Nov 14, 2022 |
| Final prospectus, with the price | Nov 16, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 16, 2022 |
| CERT · Exchange's certificate of listing | Nov 15, 2022 |
| EFFECT · Notice that a registration is effective | Nov 14, 2022 |
| F-1/A · Registration statement, amended | Nov 14, 2022 |
| CORRESP · Letter to the SEC | Nov 9, 2022 |
| CORRESP · Letter to the SEC | Nov 9, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 9, 2022 |
| CORRESP · Letter to the SEC | Nov 9, 2022 |
| F-1/A · Registration statement, amended | Nov 9, 2022 |
| UPLOAD · Letter from the SEC | Nov 8, 2022 |
All 43 filings
Open IPO · From the cover of the final prospectus (424B4) filed Nov 16, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.06M | 1.38M | 1.54M | 3.08M | 473.7K |
| Selling, general and administrative | 4.36M | 4.76M | 3.17M | 2.22M | |
| Depreciation and amortization | 38.4K | 1.06K | 11.2K | 7.57K | 1.88K |
| Interest expense | 3.86K | 5.39K | |||
| Income before tax | -3.79M | -4.88M | -8.60M | -6.87M | -2.73M |
| Income tax | 70.4K | 378.0K | 17.4K | 29.9K | |
| Net income | -3.86M | -5.25M | -8.62M | -6.89M | -2.73M |
| Earnings per share, basic | -30.35 | -67.80 | -1,703.04 | -159.11 | -88.16 |
| Earnings per share, diluted | -30.35 | -67.80 | -1,703.04 | -159.11 | -88.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 3.92M | 6.57M | 5.43M | 128.8K | 3.37M |
| Short-term investments | 1.66M | 289.4K | 86.1K | ||
| Receivables | 50.9K | ||||
| Current assets | 5.95M | 7.09M | 5.79M | 434.7K | |
| Property, plant and equipment | 1.73K | 12.9K | |||
| Total assets | 6.08M | 7.26M | 5.95M | 826.4K | |
| Accounts payable | 526.1K | 617.0K | |||
| Current liabilities | 4.89M | 4.13M | 4.97M | ||
| Total liabilities | 4.89M | 4.15M | 4.97M | 1.93M | |
| Shareholders' equity | 1.19M | 3.11M | 983.5K | -1.11M | 3.52M |
| Shares outstanding | 44.0K | 1.25M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -4.73M | -4.86M | -6.30M | -3.72M | -2.08M |
| Capital spending | -5.56K | -17.0K | |||
| Free cash flow | -3.73M | -2.09M | |||
| Cash from investing | -542.0K | -238.1K | -26.2K | -5.56K | -184.0K |
| Cash from financing | 2.62M | 6.25M | 11.7M | 511.7K | 5.39M |
| Change in cash | -2.65M | 1.15M | 5.30M | -3.24M | 3.13M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 8, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 376 filings. Open Filings
Cap table
Built by 6ix from Clearmind Medicine Inc.’s releases · as of Sep 19, 2025
- Common shares
- 507,404
- Fully diluted
- 507,404
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 507,404 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 507,404 |
| May 19, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Amitay Weiss Other companies: Maris-Tech Ltd. (Director · Since at least Mar 18, 2026); Nexera Technologies Ltd (Director · Since at least Mar 18, 2026); ParaZero Technologies Ltd. (Director · Since at least Mar 18, 2026); SciSparc Ltd. (Chairman · Since at least Oct 23, 2025); Quantum X Labs Inc. (Director · Since at least Sep 19, 2022); Nexentis Technologies Inc. (Director · Since at least Aug 26, 2020) | Chairman of the Board · Since at least Nov 5, 2026 |
| Gadi Levin Other companies: BriaCell Therapeutics Corp (Chief Financial Officer & Corporate Secretary · Since at least Aug 1, 2022); Sativus Tech Corp. (CEO · Dec 15, 2021 – Dec 15, 2021 · Past); Quantum X Labs Inc. (Chief Financial Officer · Apr 18, 2017 – Apr 18, 2017 · Past) | VP Finance · Since at least Nov 4, 2026 |
| Asaf Itzhaik Other companies: Polyrizon Ltd. (Director · Since at least Mar 18, 2026); Nexentis Technologies Inc. (Director · Since at least Dec 20, 2023) | Director · Since at least Nov 5, 2026 |
| Oz Adler Other companies: SciSparc Ltd. (Chief Executive Officer and Chief Financial Officer · Since at least Aug 19, 2026); Polyrizon Ltd. (Director · Since at least Mar 31, 2026) | Director · Since at least Mar 19, 2025 |
| Adi Zuloff-Shani Other companies: SciSparc Ltd. (Chief Technology Officer · Since at least Mar 18, 2026) | CEO · Since at least Oct 27, 2026 |
| Adi Varon | Controller · Since at least Nov 4, 2026 |
| Alan Rootenberg | Chief Financial Officer · Since at least Nov 5, 2026 |
| Hila Kiron-Revach | Director · Since at least Nov 5, 2026 |
| Mark Haden | VP Business Development · Since at least May 20, 2025 |
| Mary-Elizabeth Gifford | Chief of Global Impact · Since at least Oct 7, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Mylene Touboul | Accounting Manager · Since at least Nov 4, 2026 |
| Yehonatan Shachar | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Clearmind Medicine Inc.